Unilife (UNI.AX) (UNIFF.PK): Griffin Initiates a Buy, US$3 Target Print E-mail
Thursday, 20 August 2009 07:43

The BioMedReports.com stock research section has been updated today with a research report for Unilife Medical Solutions (UNI.AX) (UNIFF.PK) written by Keith A. Markey, PhD,  of Griffin Securities on 8/19/09 with a buy rating and $3 (U.S. Dollar) price target in addition to the most recent corporate presentation for the Company from 8/13/09. Click here for a link to coverage of Unilife at BioMedReports.com, which was initiated in late March 2009.

Highlights from the report include the following:

1.) Unilife has a disruptive drug delivery technology with a sound strategy to enter the U.S. and European needle and syringe markets

2.) Unilife has a big pharma partner in Sanofi-Aventis (NYSE:SNY), which is investing $38 million into the Company through an industrialization agreement

3.) Starting next year, additional supply agreements in other therapeutic areas (outside of the SNY agreement) are anticipated

4.) Unilife expects to obtain a U.S. listing for its stock, since it has relocated its headquarters to Pennsylvania and also has a major manufacturing facility there

Disclosure: No positions

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus